An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer
National Cancer Center Hospital East
National Cancer Center Hospital East
Baylor College of Medicine
Sichuan Baili Pharmaceutical Co., Ltd.
Asan Medical Center
Astellas Pharma Inc
Amgen
Merck Sharp & Dohme LLC
AstraZeneca
Merck Sharp & Dohme LLC
Ruijin Hospital
ImmunityBio, Inc.
Nizhny Novgorod Regional Clinical Oncology Center
Merck Sharp & Dohme LLC
Asan Medical Center
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NuCana plc
Jiangsu Hansoh Pharmaceutical Co., Ltd.
The Netherlands Cancer Institute
OncoC4, Inc.
Ukrainian Society of Clinical Oncology